September 22, 2009 - ZOLL At TCT Conference MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) firstname.lastname@example.org LIFEVEST WEARABLE DEFIBRILLATOR, AUTOPULSE, AND R SERIES CODE-READY DEFIBRILLATORS TO BE SHOWCASED BY ZOLL AT TCT CONFERENCE September 22, 2009—CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will display its range of clinical resuscitation products—including the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and the R Series® Code-Ready® defibrillators—in Booth #2001 at the Transcatheter Cardiovascular Conference September 23-25 at the Moscone Center in San Francisco. LifeVest Wearable Defibrillator The LifeVest Wearable Defibrillator is worn by patients at risk of sudden cardiac arrest (SCA), allowing their physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest, which is lightweight and easy to wear, allows patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The entire event, from detecting a life-threatening arrhythmia to automatically delivering a treatment shock, usually occurs in less than a minute. Timely defibrillation is the single most important factor in saving a SCA victim’s life. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients from SCA. The LifeVest may be prescribed for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans. To date, the LifeVest has been prescribed to more than 18,000 patients. AutoPulse Non-invasive Cardiac Support Pump Inthe catheterization lab, the AutoPulse Non-invasive Cardiac Support Pump frees clinicians to perform procedures with optimal vascular access and minimal visual compromises. Using the AutoPulse means no compromises between PCI and other actions. This exclusive technology offers the additional benefit of safeguarding staff from X-ray exposure as well as maintaining the integrity of a sterile working environment. The AutoPulseis an automated, portable device for temporary circulation support when the heart is no longer effectively circulating blood due to ventricular fibrillation or cardiac standstill. It features an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse may offer a significant advantage over manual CPR, moving blood more consistently than human providers. The device delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Over 4,200 AutoPulse devices are in use in hospital and emergency service organizations worldwide. R Series: Simple, Smart, Ready Also on display will be ZOLL’s R Series Code-Ready defibrillators, which are designed to extend simple, smart and ready defibrillation to every hospital department with advanced, cost-effective solutions for resuscitation. The R Series BLS is a simple, easy-to-use AED that becomes a full-featured, advanced life support device for critical care at the touch of a button. The R Series Plus, which offers both AED and ALS capabilities at the touch of a button, also has networking capabilities and See-Thru CPR®. Like all other ZOLL defibrillators, these models provide Real CPR Help® feedback. The original R Series ALS, launched in November 2006, and these two newer models, use the same uniform operating system common to all ZOLL defibrillators. The cables, paddles, batteries, handles, and electrodes are also common to ensure clinicians won’t encounter a mismatch in a time of crisis. In addition, all R Series models can use wireless networking to ensure code-readiness. Based on standard WiFi technology, the R Series automatically sends a status of its state of readiness at a programmed time. Early notification maximizes patient safety by giving the staff confidence that the device is ready before it is needed at a code. About ZOLL Medical Corporation ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information. ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company’s resuscitation product development. For more information, visit www.zoll.com. Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, CodeNet, LifeVest, Real CPR Help, RescueNet, See-Thru CPR, and Thermogard XP are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.